Five to seven days after the start of the stroke, Tregs infiltrate the brain parenchyma, drive microglial polarization toward the M2 phenotype, and inhibit astrocytic activation by blocking the Amphiregulin (AREG)/Epidermal Growth Factor Receptor (EGFR) pathway [141, 142]. The gene discussed is EGFR; the disease is stroke disorder.